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Chitinase 3-like 1 is neurotoxic in 
primary cultured neurons
Clara Matute-Blanch1 ✉, Laura calvo-Barreiro1, Iria carballo-carbajal2, Ricardo Gonzalo3, 
Alex Sanchez3,4, Miquel Vila2,5,6, Xavier Montalban1,7 & Manuel comabella1 ✉
Chitinase 3-like 1 (CHI3L1) is known to play a role as prognostic biomarker in the early stages of multiple 
sclerosis (MS), and patients with high cerebrospinal fluid CHI3L1 levels have an increased risk for 
the development of neurological disability. Here, we investigated its potential neurotoxic effect by 
adding recombinant CHI3L1 in vitro to primary cultures of mouse cortical neurons and evaluating both 
neuronal functionality and survival by immunofluorescence. CHI3L1 induced a significant neurite length 
retraction after 24 and 48 hours of exposure and significantly reduced neuronal survival at 48 hours. The 
cytotoxic effect of CHI3L1 was neuron-specific and was not observed in mouse immune or other central 
nervous system cells. These results point to a selective neurotoxic effect of CHI3L1 in vitro and suggest a 
potential role of CHI3L1 as therapeutic target in MS patients.
Recent studies have pointed to a prognostic role of the astrocyte-specific biomarker chitinase 3-like 1 (CHI3L1) 
in patients with clinically isolated syndrome (CIS)1,2. In an initial study conducted by our group, CIS patients 
were classified according to their conversion to clinically definite multiple sclerosis (MS)1. By applying a mass 
spectrometry-based proteomic approach, CHI3L1 was identified as one of the most differentially abundant pro-
teins in the cerebrospinal fluid (CSF) between CIS patients who converted to MS and those who remained as CIS. 
Proteomic findings were validated by ELISA and CHI3L1 levels were significantly increased in the CSF of MS 
converters and high levels were associated with a shorter time to MS compared to non-MS converters1. Based on 
these initial promising results, our group conducted a validation study of CHI3L1 as prognostic biomarker in the 
CSF of 813 CIS patients from 15 MS centres also classified according to their conversion to MS based on clinical 
and radiological criteria2. In a multivariable Cox regression analysis including radiological abnormalities at base-
line, presence of IgG oligoclonal bands, treatment, and age at CIS onset as covariates, patients with high CSF levels 
of CHI3L1 had a 4-fold increased risk for the development of neurological disability compared to CIS patients 
with low CSF CHI3L1 levels at the time of the first neurological event2. Moreover, high CSF CHI3L1 levels were 
associated with earlier disability progression (5-year difference as median time) compared to patients with low 
protein values and with sensitivity over 70%2. Interestingly, CSF CHI3L1 levels were associated with the devel-
opment of brain atrophy evaluated by the brain parenchymal fraction change after 1 and 5 years from the CIS 
event2. Based on the above-mentioned findings of a strong association between high CSF CHI3L1 levels and the 
development of neurological disability and brain atrophy in CIS patients, the question that then arises is whether 
CHI3L1 is just a mere biomarker that can be measured in the CSF and reflects the degree of astrocyte activation, 
or CHI3L1 could be neurotoxic per se. Considering that neuronal damage is responsible for the permanent neuro-
logic disability observed in MS patients3,4, in the present study we aimed to explore the potential neurotoxic effect 
of CHI3L1 by adding the protein at different concentrations in vitro to primary neuronal cultures.
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Results
CHI3L1 impairs neuronal functionality and survival. A preliminary dose-response study was first 
conducted to determine the optimal exposure conditions of cortical neurons to CHI3L1. Different CHI3L1 con-
centrations below and above 170 ng/ml (100, 300 and 600 ng/ml), a cut-off value that was demonstrated to have 
prognostic implications in CIS patients2, were tested for 24 and 48 hours. A CHI3L1 concentration of 300 ng/ml 
was selected as the lowest dose that exhibited neuronal function impairment (Fig. 1; p = 2 × 10−5 vs. control) to 
test its potential toxic effect in primary neuronal cultures.
After 24 hours of treatment, assessment of neuronal functionality with the neuron-specific cytoskeletal protein 
MAP2 revealed that CHI3L1 significantly shortened the total neurite length per cell and induced a neurite length 
retraction of 21.5% (Fig. 2A,B; p = 0.0007 vs. vehicle). This neurotoxic effect was more prominent after 48 hours 
of treatment, exposure time at which CHI3L1 induced a 25.4% of neurite length retraction (Fig. 2A,B; p = 0.0001 
vs. vehicle).
Evaluation of cell death showed that after 48 hours of treatment, CHI3L1 significantly decreased the total 
number of neurons and reduced neuronal survival by 44.0% (Fig. 2A,C; p < 0.0001 vs. vehicle), whereas no toxic 
effect was observed after 24 hours of exposure.
Glutamate, which was used as a positive control of excitotoxicity, significantly induced both neuronal func-
tion impairment and cell death following 24 and 48 hours of exposure compared to all experimental conditions 
(Fig. 2A–C).
CHI3L1 does not impair survival of immune cells and other central nervous system (CNS) cells. 
In order to determine whether the cytotoxic effect of CHI3L1 was neuron-specific or could also be observed in 
other cell types, we treated splenocytes, as representative cells from the peripheral immune system, and astrocytes 
and microglia, as representative cells from the CNS, with different concentrations (50, 100, 300 and 600 ng/ml) of 
CHI3L1 in vitro for 6, 24 and 48 hours. As shown in Fig. 3, none of the experimental conditions were associated 
with a significant effect of CHI3L1 on cell death of immune or CNS cells.
Discussion
CHI3L1 is a secreted glycoprotein member of the glycoside hydrolase 18 chitinase family that targets chitin but 
lacks enzymatic activity5. Within the CNS, CHI3L1 is mainly secreted by reactive astrocytes2,6, particularly in 
lesions with high inflammatory activity, but also by macrophages/microglial cells in lesions with low inflamma-
tory activity2. A recent validation study conducted by our group in more than 800 CSF samples confirmed a role 
of CHI3L1 as prognostic biomarker in CIS patients2. The strong association observed in CIS patients between 
high CSF CHI3L1 levels and development of disability as an independent and unique risk factor2 prompted us to 
investigate a potential neurotoxic effect of CHI3L1. Exposure of primary cultures of mouse cortical neurons to 
CHI3L1 at a concentration of 300 ng/ml resulted in a significant reduction of neurite length and neuronal sur-
vival after 48 hours. This concentration is above the 170 ng/ml cut-off value that best discriminated in our study 
between high and low CHI3L1 levels in terms of development of disability2. In line with our results, a previous 
study focused on up-regulated genes in astrocytes expressing mutated TAR DNA binding protein 43 (TDP-43), a 
causative factor in amyotrophic lateral sclerosis, also showed decreased cell viability in cortical neurons treated at 
10 DIV with CHI3L1 for 4 days, although at higher doses (500–1000 ng/ml)7. Interestingly, in our study, exposure 
of neurons to CHI3L1 was also associated with significant neurite retraction after 24 hours, indicating an early 
effect of CHI3L1 in neuronal functionality. In this context, it is widely known that dendritic structure and mor-
phology closely correlate to neuronal function and health8,9.
The fact that CHI3L1 showed no effect on the survival of disease-involved immune cells, like splenocytes, and 
other CNS cells, such as astrocytes and microglia, which are the main CHI3L1-secreting cells, supports a specific 
neurotoxic effect rather than a generalized non-specific cytotoxic effect of CHI3L1. We focused on neurons since 
Figure 1. Dose-response study of CHI3L1 neurotoxic effect. Cortical neurons from E16 mice at 11DIV were 
treated with mouse recombinant CHI3L1 (100, 300 and 600 ng/ml), glutamate (200 µM) or medium (control) 
for 24 and 48 hours. Quantitative analysis of neurite length per neuron was performed with Image J plugin 
NeuriteTracer. CHI3L1 at 300 ng/ml induced a significant shortening of neurite length after 48 hours (p = 2 × 
10−5) while 600 ng/ml showed a neurite length retraction both at 24 and 48 hours (p = 0.04 vs. control). Five 
fields (20x) of each replicate were randomly chosen, imaged and counted. Data are shown as mean ± standard 
error of the mean from 2 independent experiments with 4 replicates within each group. *p < 0.05, **p < 0.01, 
***p < 0.001 (Statistics: one-way ANOVA).
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neuronal damage is the main responsible for the permanent neurologic disability observed in patients with MS3,4. 
However, an effect of CHI3L1 in oligodendrocytes cannot be ruled out, being a limitation of the study.
Overall, these results point to a neurotoxic effect of CHI3L1 in vitro and suggest a potential role of CHI3L1 as 
therapeutic target to prevent disability progression in MS patients.
Methods
Animals. Female (9–12 week-old) and pregnant (6–10 week-old) C57BL6/J mice, E16 C57BL6/J mouse 
embryos and P0–-1 postnatal C57BL6/J mouse pups were used for primary cultures. Procedures were conducted 
in accordance with the guidelines established by the Ethical Committee for the Use of Laboratory Animals in 
Spain (Real Decreto 53/2013; Generalitat de CatalunyaDecret 214/97) and the European Ethical Committee 
(Directive 2010/63/UE). All experimental protocols were approved by the Clinical Research Ethics Committee of 
the Institut de Recerca Valld’Hebron (VHIR).
Primary neuronal cultures. Primary neuronal cultures were prepared from E16 cortices of C57BL6/J 
mouse embryos. Briefly, embryos were decapitated and brains were dissected out. Meninges, choroid plexus 
and hippocampus were removed and cortices were mechanically and enzymatically disrupted in the presence 
of trypsin and DNase I (Sigma) for 10 min at 37 °C. Cell suspensions were filtered through a 70-µm cell strainer 
and plated on coverslips precoated with 0.1 mg/ml poly-D-lysine (Sigma) in 24-well plates. Neurons were seeded 
at a density of 75,000 cells/cm2 in Advanced DMEM (Gibco) supplemented with 10% Fetal Bovine Serum (FBS, 
heat inactivated, Sigma), 20 U/ml penicillin and 20 µg/ml streptomycin (Gibco). Three hours after seeding, 
medium was replaced with serum-free Neurobasal medium (Gibco) containing 2% B27 supplement (Gibco), 1% 
GlutaMAX (100×, Gibco), 20 U/ml penicillin and 20 µg/ml streptomycin (Gibco). Culture medium was partially 
changed once per week with fresh supplemented Neurobasal medium. Cultures were maintained at 37 °C, in a 
humidified atmosphere containing 5% CO2 and treated with vehicle (PBS) or diverse concentrations of mouse 
Figure 2. Neurotoxic effect of CHI3L1. Cortical neurons from E16 mice at 11DIV were treated with PBS 
(vehicle), mouse recombinant CHI3L1 (300 ng/ml), glutamate (200 µM) or medium (control) for 24 and 
48 hours. (A) Representative images of neurons immunostained for MAP2 (red) and DAPI (blue). Scale 
bar, 100 µm. (B) Quantitative analysis of neurite length per neuron was performed with Image J plugin 
NeuriteTracer. CHI3L1 induced a significant retraction of neurite length per neuron after 24 (p = 0.0007) 
and 48 hours (p = 0.0001) compared to the vehicle. (C) Quantification of neuronal survival is expressed as 
the percentage of the mean total number of neurons respect to the control condition. After 48 hours, CHI3L1 
significantly reduced neuronal survival (p < 0.0001 vs. vehicle). (B,C) Five fields (20x) of each replicate 
were randomly chosen, imaged and counted. Data are shown as mean ± standard error of the mean from 
5 independent experiments (vehicle: n = 3) with 4 replicates within each group. *p < 0.05, **p < 0.01, 
***p < 0.001 (Statistics: one-way ANOVA).
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recombinant CHI3L1 protein (R&D Systems) for 24 and 48 hours at 11 days in vitro (DIV). Glutamate (Sigma) at 
200 µM was used as a positive control of neuronal excitotoxicity.
Primary splenocyte cultures. Spleens from five euthanized female C57BL6/J mice were removed and cell 
suspensions were obtained by grinding the spleens through a 70-μm cell strainer. Splenocytes were seeded at 
2 × 105 cells/well into 96-well plates in X-VIVO15 medium (Lonza) supplemented with 1% v/v L-glutamine 
(Biowest), 0.4% v/v penicillin-streptomycin (Gibco), 0.1M HEPES (Gibco) and 6 μM 2-β-mercaptoethanol 
(Sigma).
Primary astrocyte cultures. Purified primary astrocyte cultures were prepared from P0–1 cortices 
of C57BL6/J mouse pups. Cell suspensions were purified by magnetic cell separation (MACS) using CD11b 
MicroBeads (#130-093-634, Miltenyi Biotech) to specifically eliminate microglia from cell culture. Astrocytes 
were plated on 24-well plates precoated with 0.1 mg/ml poly-D-lysine (Sigma) and seeded at 35,000 cells/cm2 in 
Advanced DMEM (Gibco) supplemented with 10% FBS (Sigma), 20 U/ml penicillin and 20 µg/ml streptomycin 
(Gibco). The medium was changed every 3 days and cells were used for experiments at 7 DIV.
Primary mixed glial cultures. Primary mixed glial cultures were prepared from P0–1 cortices of C57BL6/J 
mouse pups. Cells were plated on  24-well plates precoated with 0.1 mg/ml poly-D-lysine (Sigma) and seeded 
Figure 3. CHI3L1 effect on immune and CNS cells. Splenocytes,astrocytes and microglia from mixed glial 
cultures were treated with PBS (vehicle), mouse recombinant CHI3L1 (50, 100, 300 and 600 ng/ml) or medium 
(control) for 6, 24 and 48 hours. (A) Quantification of splenocyte survival is expressed as the percentage of 
CD45+ alive cells respect to the control condition. (B) Quantification of astrocyte survival is expressed as the 
percentage of parental alive cells respect to the control condition. (C) Quantification of microglia is expressed as 
the percentage of CD11b+ alive cells respect to the control condition. No significant effect on cell survival was 
observed in any of the doses, time points or cell types of the study. Data are shown as mean ± standard error of 
the mean from 5 independent experiments for splenocytes and from 3 independent experiments with duplicates 
within each group for astrocytes and microglia. (Statistics: one-way ANOVA).
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at 62,500 cells/cm2 in DMEM-F12 (Gibco) supplemented with 10% FBS (Sigma), 20 U/ml penicillin and 20 µg/
ml streptomycin (Gibco). The medium was changed every 3 days and cells were used for experiments at 15 DIV.
Immunofluorescence. Neurons were fixed in cold 4% paraformaldehyde for 20 min at room temperature. 
After washing with PBS, cells were permeabilized in 0.1% Triton X-100 in PBS for 15 min and blocked with 
5% Normal Goat Serum (NGS, Millipore) in PBS for 1 h. Then, cells were incubated with mouse monoclonal 
anti-MAP2 diluted at 1:500 (microtubule-associated protein-2, #M1406, Sigma) in 1% NGS in PBS at 4 °C over-
night. After three washes with PBS, the secondary antibody goat anti-mouse Alexa Fluor 594 diluted at 1:500 
(#A11032, Invitrogen) in blocking solution was added. DAPI (4′,6-diamidino-2-phenylindole, 1:20000, Sigma) 
was used for nuclei staining and coverslips were mounted with Vectashield (Vector Laboratories). All images 
were acquired using a Leica DFC550 fluorescence microscope and LAS V4.5 visualization software (https://www.
leica-microsystems.com/) with an objective magnification of 20×.
Cell death and neurite tracing. The effect of CHI3L1 on both neuronal death and functionality was ana-
lysed on fluorescent microscopy images immunostained for DAPI and MAP2. Cell survival was assessed by quan-
tifying the mean total number of neurons after treatment respect to the control condition.Neuronal functionality 
was determined using Image J (https://imagej.nih.gov/ij/) plugin NeuriteTracer (https://fournierlab.mcgill.ca/
styled-6/NeuriteTracer.html)10. This method allows simultaneous automated nuclei counting and neurite tracing 
measurement by processing pairs of neuronal and nuclear marker images given user-defined thresholds and cor-
rection for non-specific background. Both quantifications were performed in 5 randomized fields per condition, 
each one performed in 4 replicates, from a total of 5 independent experiments (vehicle: n = 3). An average of 
1,046 neurons from each condition (Control = 1,313, vehicle = 1,397, CHI3L1 = 1,081 and glutamate = 394) per 
independent experiment were analysed.
FACS analysis. Splenocyte, astrocyte and mixed glial cultures were untreated or treated with vehicle (PBS) or 
diverse concentrations of mouse recombinant CHI3L1 protein (R&D Systems) for 6, 24 and 48 hours. The effect of 
CHI3L1 on cell death was assessed using Fixable Viability Stain 510 (BD Biosciences) and flourochrome-labeled 
anti-CD45 mAb (#561869, BD Biosciences) for splenocytes or Fixable Viability Stain 510 (BD Biosciences) and 
anti-CD11b mAb (#25-0112-81, eBioscience) for microglia. No lineage-specific marker was used for astrocyte 
analysis due to the purity of astrocyte culture. Samples were acquired with in a CytoFLEX (Beckman Coulter) 
flow cytometer and data analysis was performed with CytExpert 2.3 software (https://www.beckman.es/
flow-cytometry/instruments/cytoflex/software).
Statistical analysis. All values are expressed as the mean ± standard error of the mean (SEM). Data were 
analysed using R version 3.5.3 (https://www.r-project.org/) statistical software. Comparisons between groups 
were evaluated by one-way ANOVA with Tukey multiple comparison of means test. Outlier values were identified 
by the Grubb’s test and excluded from the analyses when applicable (α = 0.05).
Data availability
All data generated or analyzed during this study are included in this published article (and its supplementary 
information files).
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